nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

26.08.2019 | Original Article – Cancer Research

Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours

verfasst von: Ylberta Kajtazi, Daniel Kaemmerer, Jörg Sänger, Stefan Schulz, Amelie Lupp

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pancreatic adenocarcinoma (PAC) represents one of the most fatal types of cancer with an exceptionally poor prognosis, underscoring the need for improved diagnostic and treatment approaches. An over-expression of somatostatin receptors (SST) as well as of the chemokine receptor CXCR4 has been shown for many tumour entities. Respective expression data for PAC, however, are scarce and contradictory.

Methods

Overall, 137 tumour samples from 70 patients, 26 of whom were diagnosed with PAC and 44 with pancreatic neuroendocrine tumour (PanNET), were compared in terms of SST and CXCR4 expression by immunohistochemical analysis using well-characterized rabbit monoclonal antibodies.

Results

Only SST1 and CXCR4 expression was detected in PAC tumours, with SST1 present in 42.3% and CXCR4 in 7.7% of cases. However, the overall staining intensity was very weak. In contrast to the tumour cells, in many PAC cases, tumour capillaries exhibited strong SST3, SST5, or CXCR4 expression. In PanNETs, SST2 was the most-prominently expressed receptor, observed in 75.0% of the tumours at medium–strong intensity. SST5, SST1, and CXCR4 expression was detected in 20.5%, 15.9%, and 11.4% of PanNET cases, respectively, but the staining intensity was only weak. SST2 positivity in PanNET, but not in PAC, was associated with favourable patient outcomes.

Conclusions

SST or CXCR4 expression in PAC is clearly of no therapeutic relevance. However, indirect targeting of these tumours via SST3, SST5, or CXCR4 on tumour microvessels may represent a promising additional therapeutic strategy.

Annese T, Tamma R, Ruggieri S, Ribatti D (2019) Angiogenesis in pancreatic cancer: pre-clinical and clinical studies. Cancers (Basel) 11:381CrossRef

Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL (2012) Contribution of CXCR2 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 23:2327–2335CrossRefPubMed

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Fanti S (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F–DOPA. Eur J Nucl Med Mol Imaging 44:1588–1601CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRefPubMed

Buck AK, Stolzenburg A, Hänscheid H, Schirbel A, Lückerath K, Schottelius M, Wester HJ, Lapa C (2017) Chemokine receptor—directed imaging and therapy. Methods 130:63–71CrossRefPubMed

Buscail L, Saint-Laurent N, Chastre Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C (1996) Loss of SST2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56:1823–1827PubMed

Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R (1992) Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer 69:648–650CrossRefPubMed

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, For the CLARINET Investigators (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New Engl J Med 371:224–233CrossRefPubMed

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C (2015) Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3 K signaling and overexpression of CXCL16. Gastroenterology 148:1452–1465CrossRefPubMed

Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45:71–77CrossRefPubMed

Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle Fave G (2009) Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 89:223–230CrossRefPubMed

Cui K, Zhao W, Wang C, Wang A, Zhang B, Zhou W, Yu J, Sun Z, Li S (2011) The CXCR12-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Surg Res 171:143–150CrossRefPubMed

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342CrossRefPubMedPubMedCentral

Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, Walenkamp AME (2013) A review on CXCR14/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230CrossRefPubMed

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, All other Vienna Consensus Conference participants (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRefPubMed

Fazeny B, Baur M, Prohaska M, Hudec M, Kremnitzer M, Meryn S, Huber H, Grunt T, Tuchmann A, Dittrich C (1997) Octreotide combined with goserelin in the therapy of advanced pancreatic cancer—results of a pilot study and review of the literature. J Cancer Res Clin Oncol 123:45–52CrossRefPubMed

Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S (2008a) Reassessment of SST2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93:4519–4524CrossRefPubMed

Fischer T, Nagel F, Jacobs S, Stumm R, Schulz S (2008b) Reassessment of CXCR18 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One 3:e4069CrossRefPubMedPubMedCentral

Fisher WE, Muscarella P, O’Dorisio TM, O’Dorisio MS, Kim JA, Doran TA, Sabourin CL, Schirmer WJ (1996) Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery 120:234–241CrossRefPubMed

Fisher WE, Doran TA, Muscarella P II, Boros LG, Ellison EC, Schirmer WJ (1998) Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst 90:322–324CrossRefPubMed

Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG (1993) Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8:540–545CrossRefPubMed

Furusato B, Mohamed A, Uhlén M, Rhim JS (2010) CXCR22 and cancer. Pathol Int 60(497):505

Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M (2011) Prognostic impact of CXCR23 and CXCR23 expression in pancreatic adenocarcinoma. J Surg Oncol 104:140–145CrossRefPubMed

Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pinto A (2016) MIA PaCa-2 and PANC-1 pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep 6:21648CrossRefPubMedPubMedCentral

Huguier M, Samama G, Testart J, Mauban S, Fingerhut A, Nassar J, Houry S, Jaeck D, De Mestier P, Favre JP, Michot F, Vidrequin A, Mantion G, Veyrières M, Fourtanier G, Lointier P, Gignoux M (1992) Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French association for surgical research. Am J Surg 164:348–353CrossRefPubMed

Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22:9694–9705CrossRefPubMedPubMedCentral

Ingold B, Simon E, Ungethüm U, Kuban RJ, Müller BM, Lupp A, Neumann U, Ebert MP, Denkert C, Weichert W, Schulz S, Röcken C (2010) Vascular CXCR27 expression—a novel antiangiogenic target in gastric cancer? PLoS One 5:e10087CrossRefPubMedPubMedCentral

Kaemmerer D, Träger T, Hoffmeister M, Sipos B, Hommann M, Sänger J, Schulz S, Lupp A (2015a) Inverse expression of somatostatin and CXCR28 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget 6:27566–27579PubMedPubMedCentral

Kaemmerer D, Reimann C, Specht E, Wirtz RM, Sayeg M, Baum RP, Schulz S, Lupp A (2015b) Differential expression and prognostic value of the chemokine receptor CXCR29 in bronchopulmonary neuroendocrine neoplasms. Oncotarget 6:3346–3358PubMed

Kaemmerer D, Wirtz RM, Fischer EK, Hommann M, Sänger J, Prasad V, Specht E, Baum RP, Schulz S, Lupp A (2015c) Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm. Pancreas 44:648–654PubMed

Kaemmerer D, Sänger J, Arsenic R, D’Haese JG, Neumann J, Schmitt-Graeff A, Wirtz RM, Schulz S, Lupp A (2017a) Evaluation of somatostatin, CXCR31 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget 8:89958–89969CrossRefPubMedPubMedCentral

Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A (2017b) Somatostatin and CXCR32 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 17:896CrossRefPubMedPubMedCentral

Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388:73–85CrossRefPubMed

Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C (2018) CXCR34-directed theranostics in oncology and inflammation. Ann Nucl Med 32:503–511CrossRefPubMedPubMedCentral

Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, Portengen H, Foekens JA (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62:627–630CrossRefPubMedPubMedCentral

Körner M, Waser B, Schonbrunn A, Perren A, Reubi JC (2012) Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. A J Surg Pathol 36:242–252CrossRef

Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S (2000) Expression of stromal cell-derived factor 1 and CXCR37 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6:3530–3535PubMed

Kure S, Matsuda Y, Hagio M, Ueda J, Naito Z, Ishiwata T (2012) Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Int J Oncol 41:1314–1324CrossRefPubMed

Lambertini C, Barzaghi-Rinaudo P, D’Amato L, Schulz S, Nuciforo P, Schmid HA (2013) Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regul Pept 187:35–41CrossRefPubMed

Lange F, Kaemmerer D, Behnke-Mursch J, Brück W, Schulz S, Lupp A (2018) Differential somatostatin, CXCR40 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors. J Cancer Res Clin Oncol 144:1227–1237CrossRefPubMed

Liao WC, Wang HP, Huang HY, Wu MS, Chiang H, Tien YW, Lin YL, Lin JT (2012) CXCR41 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clin Transl Gastroenterol 3:e22CrossRefPubMedPubMedCentral

Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schulz S (2011) Reassessment of sst5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinology 94:255–264CrossRefPubMed

Lupp A, Nagel F, Doll C, Röcken C, Evert M, Mawrin C, Saeger W, Schulz S (2012) Reassessment of SST3 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinology 96:301–310CrossRefPubMed

Lupp A, Nagel F, Schulz S (2013) Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7. Regul Pept 183:1–6CrossRefPubMed

Mai R, Kaemmerer D, Träger T, Neubauer E, Sänger J, Baum RP, Schulz S, Lupp A (2019) Different somatostatin and CXCR45 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. Sci Rep 9:4339CrossRefPubMedPubMedCentral

Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Devière J, Salmon I, Van Laethem JL (2009) High expression of CXCR46 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 100:1444–1451CrossRefPubMedPubMedCentral

Mehta S, de Reuver PR, Gill P, Andrici J, D’Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ (2015) Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors. Medicine (Baltimore) 94:e1281CrossRef

Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M, Koizumi W (2013) Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor 2A to outcomes. Cancer 119:4094–4102CrossRefPubMed

Qian ZR, Li T, Ter-Minassian M, Yan J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH (2016) Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 45(1386):1393

Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV (1993) Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA-PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas 8:88–97CrossRefPubMed

Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10:10–27CrossRefPubMedPubMedCentral

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JGH, Lamberts SWJ (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95:760–763CrossRefPubMed

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663CrossRefPubMed

Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371:1039–1049CrossRefPubMed

Simoes P, Olson SH, Saldia A, Kurtz RC (2017) Epidemiology of pancreatic adenocarcinoma. Chin Clin Oncol 6:24CrossRefPubMed

Singh P, Townsend CM Jr, Poston GJ, Reubi JC (1991) Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts. J Steroid Biochem Mol Biol 39:759–767CrossRefPubMed

Smit Duijzentkunst DA, Kwekkeboom DJ, Bodei L (2017) Somatostatin receptor 2-targeting compounds. J Nucl Med 58:54S–60SCrossRefPubMed

Song KB, Kim SC, Kim JH, Seo DW, Hong SM, Park KM, Hwang DW, Lee JH, Lee YJ (2016) Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors. Pancreas 45:187–192CrossRefPubMed

Stollberg S, Kaemmerer D, Neubauer E, Schulz S, Simonitsch-Klupp I, Kiesewetter B, Raderer B, Lupp A (2016) Differential somatostatin and CXCR1 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol 142:2239–2247CrossRefPubMed

Sulkowski U, Buchler M, Pederzoli P, Arnold R, Dinse P, Kay A, Haus U, Beger HG (1999) A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Eur J Cancer 35:1805–1808CrossRefPubMed

Teague A, Lim KH, Wang-Gillam A (2015) Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol 7:68–84CrossRefPubMedPubMedCentral

van Eijck CH, Lamberts SW, Lemaire LC, Jeekel H, Bosman FT, Reubi JC, Bruining HA, Krenning EP (1996) The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 224:119–124CrossRefPubMedPubMedCentral

Waidmann O, Pelzer U, Boeck S, Waldschmidt DT (2018) Sequence therapy in metastatic pancreatic cancer. Z Gastroenterol 56:578–581CrossRefPubMed

Walenkamp AME, Lapa C, Herrmann K, Wester HJ (2017) CXCR65 ligands. The next big hit? J Nucl Med 58:77S–82SCrossRefPubMed

Wang Z, Ma Q, Li P, Sha H, Li X, Xu J (2013) Aberrant expression of CXCR66 and beta-catenin in pancreatic cancer. Anticancer Res 33:4103–4110PubMed

Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR, Junginger T, Galle PR, Moehler M (2006) Strong expression of chemokine receptor CXCR67 by pancreatic cancer correlates with advanced disease. Oncol Rep 16:1159–1164PubMed

Wu H, Zhu L, Zhang H, Shi X, Zhang L, Wang W, Xue H, Liang Z (2015) Coexpression of EGFR and CXCR68 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. PLoS One 10:e0116803CrossRefPubMedPubMedCentral

Zhang J, Liu C, Mo X, Shi H, Li S (2018a) Mechanisms by which CXCR69/CXCL12 cause metastatic behaviour in pancreatic cancer. Oncol Lett 15:1771–1776PubMed

Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J, Yu X (2018b) Role of angiogenesis in pancreatic cancer biology and therapy. Biomed Pharmacother 108:1135–1140CrossRefPubMed

Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B (2015) CXCR71 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget 6:5022–5040PubMed

Zhou J, Enewold L, Stojadinovic A, Clifton GT, Potter JF, Peoples GE, Zhu K (2010) Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control 21:853–861CrossRefPubMed

Titel: Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours
verfasst von: Ylberta Kajtazi
Daniel Kaemmerer
Jörg Sänger
Stefan Schulz
Amelie Lupp
Publikationsdatum: 26.08.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03011-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC

Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis

C-reactive protein as an early marker of immune-related adverse events

Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie